Literature DB >> 10477326

Formulation of biphasic release tablets containing slightly soluble drugs.

L Maggi1, E O Machiste, M L Torre, U Conte.   

Abstract

A new biphasic release system for slightly soluble drugs has been proposed. To enhance the dissolution rate, the drug was milled with a superdisintegrant. Then, double-layer tablets were prepared. One layer was formulated to release the drug in a very short time (fast-release). The other consisted of an extended-release hydroxypropylmethylcellulose (HPMC) matrix. Different HPMC concentrations (10, 16 and 22%) and viscosity grades (Methocel K4, K15 and K100M) were used to obtain different release rates of the drug from the extended-release layer, ketoprofen and praziquantel were used as slightly soluble model drugs. The in vitro dissolution tests of the prepared double-layer systems, showed the desired biphasic behaviour: the drug contained in the fast releasing layer dissolved within the first 15 min, while the drug contained in the prolonged-release layer was released at different times, depending on the formulation of the hydrophilic matrix. In particular, an increase in the percentage and viscosity grade of HPMC, in the extended release layer, leads to a decrease in the drug delivery rate and produces a wide range of different release rates from only a few hours up to 24 h.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10477326     DOI: 10.1016/s0939-6411(99)00019-3

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  9 in total

1.  Development of modified-release tablets of zolpidem tartrate by biphasic quick/slow delivery system.

Authors:  Anjan Kumar Mahapatra; N H Sameeraja; P N Murthy
Journal:  AAPS PharmSciTech       Date:  2014-11-13       Impact factor: 3.246

2.  Design and evaluation of a novel matrix type multiple units as biphasic gastroretentive drug delivery systems.

Authors:  Meka Lingam; Thadisetty Ashok; Vobalaboina Venkateswarlu; Yamsani Madhusudan Rao
Journal:  AAPS PharmSciTech       Date:  2008-12-31       Impact factor: 3.246

3.  Hydrophilic matrices for controlled drug delivery: an improved mathematical model to predict the resulting drug release kinetics (the "sequential layer" model).

Authors:  J Siepmann; N A Peppas
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

4.  Design and in vitro evaluation of novel sustained-release double-layer tablets of lornoxicam: utility of cyclodextrin and xanthan gum combination.

Authors:  Yassin El-Said Hamza; Mona Hassan Aburahma
Journal:  AAPS PharmSciTech       Date:  2009-11-18       Impact factor: 3.246

5.  Sustained-release praziquantel tablet: pharmacokinetics and the treatment of clonorchiasis in beagle dogs.

Authors:  Sung-Tae Hong; Sang Hyup Lee; Seung-Jin Lee; Weon-Gyu Kho; Mejeong Lee; Shunyu Li; Byung-Suk Chung; Min Seo; Min-Ho Choi
Journal:  Parasitol Res       Date:  2003-08-28       Impact factor: 2.289

6.  Compressed matrix core tablet as a quick/slow dual-component delivery system containing ibuprofen.

Authors:  Carla Martins Lopes; José M Sousa Lobo; João F Pinto; Paulo C Costa
Journal:  AAPS PharmSciTech       Date:  2007-09-21       Impact factor: 3.246

7.  Chitosan and enteric polymer based once daily sustained release tablets of aceclofenac: in vitro and in vivo studies.

Authors:  Srinivas Mutalik; Krishnan Manoj; Meka Sreenivasa Reddy; Pralhad Kushtagi; Achutha Nayak Usha; Parambil Anju; Averineni Kumar Ranjith; Nayanabhirama Udupa
Journal:  AAPS PharmSciTech       Date:  2008-05-24       Impact factor: 3.246

8.  Controlled release hydrophilic matrix tablet formulations of isoniazid: design and in vitro studies.

Authors:  Praveen S Hiremath; Ranendra N Saha
Journal:  AAPS PharmSciTech       Date:  2008-11-19       Impact factor: 3.246

9.  Oral drug delivery systems using core-shell structure additive manufacturing technologies: a proof-of-concept study.

Authors:  Jiaxiang Zhang; Pengchong Xu; Anh Q Vo; Michael A Repka
Journal:  J Pharm Pharmacol       Date:  2021-03-04       Impact factor: 3.765

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.